Business
Ovid Therapeutics to Present at Upcoming September Investor Conferences
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people
About this update from Ovid Therapeutics Inc.
NEW YORK , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference – Ovid will present on September 10th at 3:30 p.m. ET . Cantor Global Healthcare Conference – Ovid will participate in a fireside chat on Tuesday, September 17th at 1:55 p.m. ET . Live webcasts of the fireside chat and presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com . An archived replay of the webcast will be available on the Company’s website following the live presentation. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York -based biopharmaceutical company that is dedicated to improving the lives of people affected by rare epilepsies and brain conditions with seizure symptoms. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing: OV888/GV101 capsule, a potent and highly selective ROCK2 inhibitor, for the potential treatment of cerebral cavernous malformations and other rare central nervous system diseases; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com . Investor Relations: Garret Bonney 617-735-6093 [email protected] Source: Ovid Therapeutics Inc.
View stock analysis, news, and events for Ovid Therapeutics Inc.